Profil bibliographique

Kohei Shitara

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

15Publications signalées

12Citations signalées

1Affiliations récentes

Les institutions déclarées

Les domaines associés

HER2/EGFR in Cancer ResearchGastric Cancer Management and OutcomesCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesEsophageal Cancer Research and Treatment

Les publications récentes

2026 conference-abstract OpenAlex

Characterization and management of gastrointestinal (GI) adverse events (AEs) with zanidatamab + chemotherapy (CT) ± tislelizumab in first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): Analysis from HERIZON-GEA-01.

Elena Elimova, Sun Young Rha, Kohei Shitara, Tianshu Liu et autres

ca, kr, jp, cn, ro, au, us, my, es, it, tw, fr (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): PD-L1 subgroup analysis from HERIZON-GEA-01.

Sun Young Rha, Kohei Shitara, L Shen, J Tabernero et autres

kr, jp, cn, ro, au, us, my, es, it, tw, fr, ca (code pays fourni par la source)

1 citation Journal of Clinical Oncology

Accès ouvert 2026 conference-abstract OpenAlex

Additional health-related quality of life (HRQoL) analysis from DESTINY-Gastric04 (DG-04), a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) unresectable/metastatic gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA).

Kohei Shitara, Aziz Zaanan, Sara Lonardi, Christelle De La Fouchardiere et autres

jp, fr, it, be, cn, us, de, gb, kr, tr (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

Heterogeneity in biomarkers for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC) across regions: Insights from CheckMate-649.

L Shen, Kohei Shitara, Markus H. Moehler, Jaffer A. Ajani et autres

cn, jp, de, us, cl, pl, ca (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

KEYNOTE-811: 6-year median follow-up of pembrolizumab plus trastuzumab and chemotherapy for previously untreated advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Akihito Kawazoe, Sun Young Rha, Yuxian Bai, Jianming Xu et autres

jp, kr, cn, it, fr, cl, pl, ua, tr, be, us (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

Neoadjuvant and adjuvant pembrolizumab plus chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: Outcomes from the microsatellite instability-high population of the phase 3 KEYNOTE-585 study.

Sun Young Rha, Lucjan Wyrwicz, Yung-Jue Bang, Hisateru Yasui et autres

kr, pl, Éthiopie, jp, ru, de, cl, it, il, us (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX in patients with HER2-low gastroesophageal adenocarcinoma (EPOC2203).

Yu Aoki, Izuma Nakayama, Masashi Wakabayashi, Hiroki Hara et autres

jp, us (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

ctDNA dynamics and prognostic value during first-line treatment of metastatic colorectal cancer: Analysis from the phase 3 PARADIGM study.

Kentaro Yamazaki, Riu Yamashita, Takayuki Yoshino, Kohei Shitara et autres

jp (code pays fourni par la source)

0 citations Journal of Clinical Oncology

Accès ouvert 2026 conference-abstract OpenAlex

Tumor and immune microenvironment remodeling with neoadjuvant trastuzumab deruxtecan in HER2-positive gastric cancer: Exploratory analyses from the phase 2 EPOC2003 study.

Akihito Kawazoe, Daisuke Takahari, Akiko Tamura, Kota Itahashi et autres

jp, gb, us, de (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

First-line (1L) trastuzumab deruxtecan (T-DXd)–based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.

Yelena Y. Janjigian, Hirokazu Shoji, Anna Kowalczyk, Sun Young Rha et autres

us, jp, pl, kr, it, es, nl, cn, br, ca, sg (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

Sonesitatug vedotin (Sone-Ve) monotherapy in patients (pts) with claudin 18.2–positive (CLDN18.2+) advanced or metastatic gastric or gastroesophageal junction (GEJ) cancers: Data from CLARITY-PanTumor01.

Kohei Shitara, Kensei Yamaguchi, Hirokazu Shoji, Jeeyun Lee et autres

jp, kr, au, es, us, ca, nl, sg, br (code pays fourni par la source)

1 citation Journal of Clinical Oncology

2026 conference-abstract OpenAlex

Zongertinib combined with T-DXd in HER2-positive metastatic gastric, gastroesophageal junction, or esophageal carcinoma (mGEAC): First results from a phase Ib/II dose-escalation trial.

Izuma Nakayama, Bernard Gaston Doger de Spéville, David Berz, Silvia Foti et autres

jp, es, us, it, cn, de, at (code pays fourni par la source)

0 citations Journal of Clinical Oncology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.